Drug intelligence / Profile preview

Acetoxolone

Development stage: Unknown
Modality: Small Molecules
Administration: Oral

Overview

Acetoxolone is a small molecule triterpenoid drug, specifically an acetyl derivative of glycyrrhetinic acid. It has been used for the treatment of peptic ulcer and gastroesophageal reflux disease (GERD). Acetoxolone acts as an inhibitor of 11β-hydroxysteroid dehydrogenase (11β-HSD), which may contribute to its protective effects on the gastric mucosa. The compound is found naturally in Echinopora lamellosa and belongs to the class of organic compounds known as triterpenoids.

Other names: acetylglycyrrhetic acidacetylglycyrrhetinic acidglycyrrhetinyl acetateglycyrrhetic acid acetate

Targets

HSD11B2 (11β-HSD2)HSD11B1 (11-beta-hydroxysteroid dehydrogenase type 1)

Beyond the preview

Go deeper on Acetoxolone.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Acetoxolone.

Explore the full profile